A Phase 2 interventional study of DENOSUMAB in Relapsed or Plateau-Phase Multiple Myeloma, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-15.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Multiple Myeloma by Amgen — none open to participants now, none under way, none of them phase 3. Multiple Myeloma · Amgen.
Among the 43 studies in Multiple Myeloma by Amgen, this one is the 22nd largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2005, is one of 10 in phase 2, and was the 4th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →None of the 43 studies in Multiple Myeloma by Amgen is open now. The open studies under Multiple Myeloma, anywhere →
Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 16 · Phase 3 11 · Phase 4 1
First in 2005; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 101 across the 40 interventional studies, 705 across the 1 observational. Of the 41 that completed or were terminated, 36 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 43 studies in Multiple Myeloma by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if denosumab is effective in the treatment of relapsed or plateau-phase multiple myeloma.
Patients who have relapsed myeloma have failed treatment regimens and have had disease progression following their last treatment regimen. Despite newer salvage therapies, their treatment options are limited and may include best supportive care and investigational therapy. Patients with plateau-phase myeloma have a stabilized serum M-protein level without further tumor regression despite continued treatment. Recent evidence suggests that their prognosis might improve with further reduction in serum M-protein or prolongation of time to disease progression (TTP). These patients are candidates for investigational agents that could further reduce tumor burden or increase TTP.
3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
This study's enrollment of 96 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other criteria also apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DENOSUMAB
120 mg administered subcutaneously on study days 1, 8, 15, and 29 and every 28 days thereafter. Each dose will be administered in two separate injections of 60 mg (1.0 mL) each.
Complete Response or Partial Response Based on M-Protein Assessments Only
Complete response or partial response based on serum M-Protein assessments. Complete response is defined as absence of original M-protein in serum by immunofixation, and partial response is defined as ≥ 50% reduction from baseline in serum M-protein, both maintained for a minimum of 6 weeks.
Time frame: Up to 18 months
Complete Response, Partial Response or Minimal Response Based on M-Protein Assessments Only
Complete response, partial response or minimal response based on serum M-protein assessments. Complete and partial responses are as defined for the primary outcome measure. Minimal response is defined as 25 to 49% reduction from baseline in serum M-protein level, maintained for a minimum of 6 weeks.
Time frame: Up to 18 months
Complete Response Based on M-Protein Assessments Only
Complete response based on M-protein assessments, as defined for the primary outcome measure.
Time frame: Up to 18 months
Participants were enrolled from 13 February 2006 through 8 December 2006
| Milestone | Denosumab 120 mg Q4W - Plateau-Phase | Denosumab 120 mg Q4W - Relapsed |
|---|---|---|
| Started | 43 | 53 |
| Received study medication | 42 | 53 |
| Completed | 0 | 0 |
| Not completed | 43 | 53 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Withdrawal by subject | 2 | 6 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Disease progression | 19 | 36 |
| Withdrew: Ongoing | 17 | 3 |
| Withdrew: Other | 3 | 0 |
| Withdrew: Requirement for alternative therapy | 0 | 4 |
Complete response or partial response based on serum M-Protein assessments. Complete response is defined as absence of original M-protein in serum by immunofixation, and partial response is defined as ≥ 50% reduction from baseline in serum M-protein, both maintained for a minimum of 6 weeks.
| Participants | Denosumab 120 mg Q4W - Plateau-Phase | Denosumab 120 mg Q4W - Relapsed |
|---|---|---|
| Complete Response or Partial Response Based on M-Protein Assessments Only | 0 | 0 |
Complete response, partial response or minimal response based on serum M-protein assessments. Complete and partial responses are as defined for the primary outcome measure. Minimal response is defined as 25 to 49% reduction from baseline in serum M-protein level, maintained for a minimum of 6 weeks.
| Participants | Denosumab 120 mg Q4W - Plateau-Phase | Denosumab 120 mg Q4W - Relapsed |
|---|---|---|
| Complete Response, Partial Response or Minimal Response Based on M-Protein Assessments Only | 0 | 0 |
Complete response based on M-protein assessments, as defined for the primary outcome measure.
| Participants | Denosumab 120 mg Q4W - Plateau-Phase | Denosumab 120 mg Q4W - Relapsed |
|---|---|---|
| Complete Response Based on M-Protein Assessments Only | 0 | 0 |
Collected over up to 1 year 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab 120 mg Q4W - Relapsed | — | 14/53 (26.4%) | 38/53 (71.7%) |
| Denosumab 120 mg Q4W - Plateau-Phase | — | 6/42 (14.3%) | 32/42 (76.2%) |
| Event | Denosumab 120 mg Q4W - Relapsed | Denosumab 120 mg Q4W - Plateau-Phase |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/53 | 0/42 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/53 | 0/42 |
| Multiple myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/53 | 0/42 |
| Renal failureRenal and urinary disorders | 2/53 | 0/42 |
| Intestinal obstructionGastrointestinal disorders | 0/53 | 1/42 |
| Intestinal perforationGastrointestinal disorders | 0/53 | 1/42 |
| Haemophilus infectionInfections and infestations | 0/53 | 1/42 |
| PneumoniaInfections and infestations | 1/53 | 1/42 |
| Septic shockInfections and infestations | 0/53 | 1/42 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/53 | 1/42 |
| Event | Denosumab 120 mg Q4W - Relapsed | Denosumab 120 mg Q4W - Plateau-Phase |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 9/53 | 12/42 |
| FatigueGeneral disorders | 8/53 | 8/42 |
| HeadacheNervous system disorders | 4/53 | 8/42 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/53 | 7/42 |
| AnaemiaBlood and lymphatic system disorders | 8/53 | 3/42 |
| DiarrhoeaGastrointestinal disorders | 7/53 | 6/42 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/53 | 3/42 |
| Back painMusculoskeletal and connective tissue disorders | 7/53 | 4/42 |
| Oedema peripheralGeneral disorders | 0/53 | 5/42 |
| NauseaGastrointestinal disorders | 6/53 | 4/42 |
| Age, Continuous(Years) | Denosumab 120 mg Q4W - Plateau-Phase | Denosumab 120 mg Q4W - Relapsed | Total |
|---|---|---|---|
| Mean | 61.1 ± 11.4 | 62.9 ± 9.2 | 62.1 ± 10.2 |
| Sex: Female, Male(Participants) | Denosumab 120 mg Q4W - Plateau-Phase | Denosumab 120 mg Q4W - Relapsed | Total |
|---|---|---|---|
| Female | 26 | 13 | 39 |
| Male | 17 | 40 | 57 |
| Race/Ethnicity, Customized(Participants) | Denosumab 120 mg Q4W - Plateau-Phase | Denosumab 120 mg Q4W - Relapsed | Total |
|---|---|---|---|
| Caucasian | 35 | 39 | 74 |
| African American | 4 | 7 | 11 |
| Hispanic or Latino | 1 | 3 | 4 |
| Other | 3 | 4 | 7 |
No study locations are listed for this record.
The record gives a start of Nov 2005, a primary completion of Aug 2007 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 3 years 5 months after primary completion. A results delay was requested in Nov 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab